Insider Transactions in Q1 2024 at Pliant Therapeutics, Inc. (PLRX)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 23
2024
|
Bernard Coulie President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
128,150
+22.38%
|
-
|
|
Jan 23
2024
|
Lily Cheung Chief Human Resource Officer |
BUY
Grant, award, or other acquisition
|
Direct |
26,000
+49.25%
|
-
|
|
Jan 23
2024
|
Keith Lamont Cummings Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
55,250
+18.11%
|
-
|
|
Jan 23
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+26.64%
|
-
|
|
Jan 23
2024
|
Hans Hull Chief Business Officer |
BUY
Grant, award, or other acquisition
|
Direct |
31,500
+12.7%
|
-
|
|
Jan 23
2024
|
Eric Lefebvre Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
42,900
+17.67%
|
-
|
|
Jan 17
2024
|
Keith Lamont Cummings Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,781
-4.79%
|
$166,277
$17.23 P/Share
|
|
Jan 17
2024
|
Eric Lefebvre Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
10,295
-6.16%
|
$175,015
$17.23 P/Share
|
|
Jan 17
2024
|
Bernard Coulie President and CEO |
SELL
Open market or private sale
|
Direct |
25,721
-7.52%
|
$437,257
$17.23 P/Share
|
|
Jan 17
2024
|
Hans Hull Chief Business Officer |
SELL
Open market or private sale
|
Direct |
9,786
-5.02%
|
$166,362
$17.23 P/Share
|
|
Jan 17
2024
|
Mike Ouimette General Counsel & Corp. Sec'y |
SELL
Open market or private sale
|
Direct |
5,197
-8.6%
|
$88,349
$17.23 P/Share
|